Alnylam Execs Foresee Partnerships in 2010, Provide Few Details as Pipeline Advances
March 04, 2010
Alnylam Execs Foresee Partnerships in 2010, Provide Few Details as Pipeline Advances
Alnylam's top official said that while the company is encouraged that it will be able to confirm efficacy data observed in a phase IIa trial of its respiratory syncytial virus treatment ALN-RSV01, he stressed that it may not be able to do so in a follow-up study initiated late last month.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News - Alnylam Provides Pipeline Update, Completes Phase I Trial of Liver Cancer Drug
August 4, 2011 / Gene Silencing News - Alnylam Q3 Losses Up as R&D Costs Increase
November 4, 2010 / Gene Silencing News - RXi Q1 Loss Rises on Opko Deal Charge
May 16, 2013 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News